World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
87
Citations
39766
World Ranking
1193
National Ranking
41

Medicine

D-Index
87
Citations
40011
World Ranking
13422
National Ranking
439

Overview

Jonathan Cebon is a researcher affiliated with La Trobe University in Australia. Their work primarily spans the fields of Medicine and Immunology and Microbiology, with a significant focus on Oncology, Immunology, Molecular Biology, Surgery, and Pulmonary and Respiratory Medicine.

Their main research topics include:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Vaccines and immunoinformatics approaches
  • Ovarian cancer diagnosis and treatment

Jonathan Cebon has contributed to several journals with multiple publications in key venues such as Clinical Cancer Research, JAMA Oncology, Journal for ImmunoTherapy of Cancer, Cell Death Discovery, and Annals of Oncology.

Frequent co-authors collaborating with them include:

  • Andreas Behren
  • Matteo S. Carlino
  • Oliver Klein
  • Damien Kee
  • Jodie Palmer

Notable recent papers authored by Jonathan Cebon encompass the following:

  • Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells, 2020, Science
  • Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers, 2020, JAMA Oncology
  • Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers, 2020, Clinical Cancer Research
  • Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma, 2021, Nature Immunology
  • Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma, 2020, Science Advances

Best Publications

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

    Mark R Middleton;J J Grob;N Aaronson;G Fierlbeck

  • Whole-genome landscapes of major melanoma subtypes

    Nicholas K. Hayward;Nicholas K. Hayward;James S. Wilmott;Nicola Waddell;Nicola Waddell;Peter A. Johansson

  • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    Antoni Ribas;Reinhard Dummer;Igor Puzanov;Ari VanderWalde

  • Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology

    Edouard Stanley;Graham J. Lieschke;Graham J. Lieschke;Dianne Grail;Donald Metcalf

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

    Marian L Burr;Marian L Burr;Marian L Burr;Christina E Sparbier;Yih-Chih Chan;James C Williamson

  • Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells

    Thomas Luft;Ken C Pang;Elisabeth Thomas;Paul J Hertzog

  • Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

    Ian D. Davis;Weisan Chen;Heather Jackson;Phillip Parente;Phillip Parente

  • Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets

    Thomas Luft;Michael Jefford;Petra Luetjens;Tracey Toy

  • Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells.

    Marc Rigau;Marc Rigau;Simone Ostrouska;Thomas S Fulford;Darryl N Johnson

  • Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

    Georgina Long;Jeffrey s Weber;Jeffrey R Infante;Kevin B Kim

  • Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial

    Darryl W. Maher;Graham J. Lieschke;Michael Green;James Bishop

  • Tumor antigen expression in melanoma varies according to antigen and stage

    Catherine Barrow;Judy Browning;Duncan MacGregor;Ian D. Davis

  • Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer

    Russell L. Basser;John E.J. Rasko;Kerrie Clarke;Jonathan Cebon

  • Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

    Mario Sznol;Pier Francesco Ferrucci;David Hogg;Michael B Atkins

  • Large Scale Identification of Human Hepatocellular Carcinoma-Associated Antigens by Autoantibodies

    Yu Wang;Ke-Jun Han;Xue-Wen Pang;Hilary A. Vaughan

  • Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

    Georgina V. Long;Georgina V. Long;Victoria Atkinson;Victoria Atkinson;Jonathan S. Cebon;Michael B. Jameson

Frequent Co-Authors

Ian D. Davis
Ian D. Davis Monash University
Weisan Chen
Weisan Chen La Trobe University
Eugene Maraskovsky
Eugene Maraskovsky CSL (United Kingdom)
Georgina V. Long
Georgina V. Long University of Sydney
Richard F. Kefford
Richard F. Kefford Macquarie University
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Lloyd J. Old
Lloyd J. Old Ludwig Cancer Research
Alexander Dobrovic
Alexander Dobrovic University of Melbourne
Andrew M. Scott
Andrew M. Scott La Trobe University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology opens diverse career pathways, particularly in healthcare and research. For those interested in advanced clinical roles, pursuing an acute care NP certification can be a valuable step. This certification allows nurse practitioners to specialize in managing patients with complex conditions, complementing immunology expertise.

Nursing professionals looking to accelerate their careers can explore an accelerated NP program. These programs offer a fast-track route to becoming a nurse practitioner, combining clinical knowledge with specialized immunological skills.

For individuals without a nursing background, online accelerated nursing programs for non nurses provide an accessible pathway into nursing. These programs help bridge the gap from other fields into nursing careers, laying the groundwork for advanced studies in immunology-related healthcare roles.

Additionally, those seeking easy entry into nursing can consider absn programs with high acceptance rates. These accelerated Bachelor of Science in Nursing programs offer flexible options to start a nursing career sooner, which can pair well with further immunology specialization.

Best Scientists Citing Jonathan Cebon

Trending Scientists